What the FDA decided on Besremi for Essential thrombocythemia
The FDA approved Besremi (ropeginterferon alfa-2b-njft) for essential thrombocythemia.
Label expansion into essential thrombocythemia, the first new FDA-approved ET treatment in nearly 30 years (PharmaEssentia release, August 31, 2026). Approved for adults regardless of genotype, including newly diagnosed patients. In the Phase 3 SURPASS ET trial against anagrelide, 37.4% of Besremi patients had a durable response at months 9 and 12 versus 3.6% on anagrelide.
Who the Besremi decision matters to
Essential Thrombocythemia is a myeloproliferative neoplasm characterized by overproduction of platelets by bone marrow, resulting in very high platelet counts. Patients are at increased risk for blood clots and, paradoxically, bleeding complications.
Many cases involve mutations in JAK2, CALR, or MPL genes.
Prevalence: About 1 new case per 100,000 people each year, with an estimated 30 to 60 per 100,000 living with it (NORD); average age at diagnosis is in the mid-fifties. See our full Essential Thrombocythemia page for current treatments, recruiting trials, and community resources.
How Besremi works
Besremi: pegylated interferon alfa-2b that binds the interferon alfa receptor (IFNAR) on bone marrow cells and switches on JAK1, TYK2 and STAT signaling; the label says the exact way it controls polycythemia vera and essential thrombocythemia is not fully understood. Our full Besremi profile covers how it works, side effects in plain language, and its trial history.
Where Essential Thrombocythemia treatment stands today
Read our full Essential Thrombocythemia treatment summary
Research in Essential Thrombocythemia is evolving toward personalized treatment strategies that account for your specific genetic makeup and risk profile. Clinical trials are testing targeted JAK inhibitors, HDAC inhibitors, and innovative agents designed to reduce platelet production while preserving quality of life and keeping side effects manageable.
Understanding your mutation status, genetic risk, and individual clot and bleeding risk allows your hematologist to tailor therapy specifically to your situation. Hydroxyurea has long been the usual first medicine to lower platelets, and anagrelide and, since August 28, 2026, Besremi are FDA approved for this condition.
Discussing trial opportunities with your hematologist is an important part of developing a comprehensive treatment plan suited to your needs.
The Essential Thrombocythemia page has every treatment and trial →Meanwhile, 38 Essential Thrombocythemia studies are open or about to open
The FDA's decision does not end research on Essential Thrombocythemia. Of these, 29 test a treatment; the others follow patients over time. The most recently updated:
You'll hear about future FDA decisions and new recruiting trials for Essential Thrombocythemia. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Frequently asked questions
Has the FDA decided on Besremi?
The FDA has already decided. It approved the application.
Details: the outcome and what it means are at the top of this page.
Source: FDA approval notice
What was Besremi approved for?
The FDA approved PharmaEssentia's sBLA for Besremi in Essential thrombocythemia.
What to know: Label expansion into essential thrombocythemia, the first new FDA-approved ET treatment in nearly 30 years (PharmaEssentia release, August 31, 2026). Approved for adults regardless of genotype, including newly diagnosed patients. In the Phase 3 SURPASS ET trial against anagrelide, 37.4% of Besremi patients had a durable response at months 9 and 12 versus 3.6% on anagrelide.
How it works: Pegylated interferon alfa-2b that binds the interferon alfa receptor (IFNAR) on bone marrow cells and switches on JAK1, TYK2 and STAT signaling; the label says the exact way it controls polycythemia vera and essential thrombocythemia is not fully understood.
More: the Besremi drug page explains it in plain language.
Is there already an FDA-approved treatment for Essential Thrombocythemia?
Yes. Trial Friend's drug list includes 1 FDA-approved drug for Essential Thrombocythemia.
Approved: Besremi (ropeginterferon alfa-2b-njft).
Check: the Essential Thrombocythemia page also searches FDA drug labels for approved treatments.
What did the Besremi trials show?
SURPASS ET (NCT04285086) randomized 174 adults with essential thrombocythemia whose disease had not responded well enough to hydroxyurea, or who could not tolerate it, to Besremi (91) or anagrelide pills (83) for 12 months; 96% of patients were Asian, 82% had a JAK2 V617F mutation and 12% a CALR mutation. A durable response at both month 9 and month 12, meaning platelets at or below 400 x 10^9/L, white cells below 9.5 x 10^9/L, no spleen growth and no bleeding or clotting events, occurred in 37.4% on Besremi vs 3.6% on anagrelide.
More: the Besremi drug page has the full trial history and sources.
What are the side effects of Besremi?
Besremi has a boxed warning. Interferon alfa products can cause or worsen fatal or life-threatening neuropsychiatric, autoimmune, ischemic (reduced blood flow) and infectious disorders, and treatment is stopped if these stay severe or keep getting worse.
Most common: Raised liver enzymes (54% vs 14% on anagrelide in SURPASS ET), Fever (26% vs 9%), Bacterial infection (24% vs 23%), Itching (22% vs 19%), Weight loss (21% vs 6%), Flu-like illness (59% in PEGINVERA, polycythemia vera).
Boxed warning: Interferon alfa products, including Besremi, can cause or worsen fatal or life-threatening neuropsychiatric, autoimmune, ischemic and infectious disorders; treatment is stopped if signs stay severe or keep getting worse.
More: the Besremi drug page has the label's warnings in full.
How much will Besremi cost?
Trial Friend does not list a price for Besremi. What you pay depends on your insurance and on help from the drugmaker or a charity fund.
Drugmaker help: PharmaEssentia SOURCE.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Besremi decision?
The FDA approved Besremi for Essential thrombocythemia on August 28, 2026.
Next steps: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
Where this outcome comes from
The outcome on this page comes from FDA approval notice. This page rechecks against our calendar, which is re-verified daily.